City Research Online

Abstract

Background
Adoptive cell therapy with tumour-infiltrating lymphocytes has been recognised as a safe and effective treatment for patients with advanced melanoma. Whether such a novel intervention is cost-effective remains unclear. The aim of this research is to evaluate the cost-effectiveness of this intervention for advanced melanoma by systematically reviewing the existing literature.

Methods
Electronic databases (including MEDLINE, EMBASE, PubMed, Web of Science, Cochrane Trials, ClinicalTrials.gov, CINAHL, Academic Search Ultimate, Centre for Reviews and Dissemination’s National Health Service Economic Evaluation Database, and citations) were searched for published cost-effectiveness studies from 2000.

Results
A total of two studies met the inclusion criteria of a full economic evaluation. According to both studies, this novel intervention is deemed as cost-effective for advanced melanoma compared to standard treatment ipilimumab in a Dutch and Danish setting. The finding supports reimbursement of this intervention and lead to its inclusion as treatment guidelines for patients with advanced melanoma.

Conclusions
However, given the little research relating to its cost-effectiveness, further clinical trial investigations could be the next step of research in the UK and other European countries would be invaluable for these healthcare systems and their patients.

Data availability
All data analysed during this study are included in its supplementary information files. Supplementary information: Supplementary Table (1) Search strategy for EMBASE; Supplementary Table (2) Quality assessment result of included studies using the QHES; Supplementary Table (3) Completed PRISMA Checklist.

Publication Type:	Article
Additional Information:	This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher Keywords:	Tumour-infiltrating lymphocytes, standard treatment, advanced melanoma, economic evaluation, systematic review
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Departments:	School of Health & Medical Sciences School of Health & Medical Sciences > Department of Population Health & Policy
SWORD Depositor:	Symplectic Administrator

Export

Downloads